DRTS Stock — Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. (DRTS)

Updated October 16, 2026.

DRTS is a Stock. Total return is 21.7% over the past 5.6 years, 94.2 points behind SPY at 115.9%.

Alpha Tau Medical is a clinical-stage oncology company developing Alpha-DaRT (diffusing alpha-emitters radiation therapy), a novel approach to treating solid tumors including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. The company's technology is currently in clinical trials for multiple cancer types and has a strategic collaboration for prostate cancer development. As an early-stage therapeutics company without approved products, it does not currently distribute income and appeals primarily to investors with high risk tolerance seeking exposure to innovative cancer treatment development.

DRTS performance versus SPY

Price and return data through 2026-10-16.

Total return is 21.7% over the past 5.6 years, 94.2 points behind SPY at 115.9%. Over the past year its total return — price change plus distributions reinvested — is 215.9%. Its deepest 1-year drawdown was 23.9%.

DRTS key facts

Asset type

Stock

Asset class

Equity

Inception date

03/08/2021

Distribution frequency

None

Last close

$12.29 (as of 2026-10-16)

Market cap

$1,136,556,513

Average volume

778682.0

Beta

1.206

Payout ratio

0.0%

EPS

$-1.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DRTS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 23.9%.

Who may consider DRTS — and who may not

It is a weaker fit for investors who need monthly cash flow (DRTS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DRTS

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions